Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN News Highlights

Back to Item »

FDA Details “Reasonable and Feasible” Trial Design for Orexigen’s Obesity Drug Contrave

Agency says interim analysis of proposed CVOT could be sufficient for resubmission of NDA.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

Myriad Genetics Trial: Your Thoughts?

Do you agree with the Supreme Court’s decision in the Myriad case?

Suggest a Poll